Hard vs. Soft Gelatin Capsules: Key Technical Differences for Pharmaceutical Buyers

Gelatin capsules account for a significant share of all solid oral dosage forms manufactured globally — the raw material decision that underlies them is one of the most consequential a pharmaceutical procurement or formulation team makes.

Yet the choice between hard gelatin capsules (HGC) and soft gelatin capsules (SGC) is frequently treated as a given rather than a decision, with buyers defaulting to whichever format the contract manufacturer runs, rather than specifying on technical grounds.

This guide is written for the buyers, formulation scientists, and quality managers who need to understand the technical distinctions between HGC and SGC — shell composition, gelatin grade requirements, fill compatibility, dissolution behaviour, crosslinking risk, and regulatory documentation — as a framework for making defensible sourcing decisions.

Pharmaceutical gelatin sits at the intersection of food safety law, pharmacopoeial regulation, and advanced drug delivery science. For the broader context of how gelatin functions as a platform biomaterial in pharmaceutical and biomedical applications, the EGA's analysis of gelatin in regenerative medicine provides relevant background on gelatin's biocompatibility profile — a property that underlies its suitability across pharmaceutical dosage forms.

What Is Pharmaceutical Gelatin? Raw Material Baseline

Pharmaceutical gelatin is collagen hydrolysate produced under conditions that satisfy pharmacopoeial quality standards. The primary raw material sources are porcine hides (Type A, acid process) and bovine hides and bones (Type B, alkaline process). The acid process used for porcine gelatin completes in days; the alkaline liming required for bovine feedstocks takes 30 to 100 days — a lead time difference with direct implications for supply chain responsiveness.

The pharmacopoeial reference for pharmaceutical gelatin is Ph. Eur. Monograph 0330 (Gelatina), with parallel specifications in USP Gelatin General Notices and BP Gelatin. Key quality parameters include:

Type A vs. Type B: What the Process Difference Means for Buyers

Type A porcine gelatin is produced by acid pre-treatment, yielding a product with a higher isoelectric point (pH 7–9) compared to Type B bovine gelatin (pH 4.8–5.5). This difference in surface charge affects how the gelatin interacts with certain APIs and dyes, which is relevant for both HGC manufacturing parameters and crosslinking risk assessment. European producers sourcing from local pork supply chains — including established manufacturers such as Brodnica Gelatin, Poland's dedicated porcine gelatin producer — supply Type A gelatin with full TSE/BSE compliance documentation under Ph. Eur. 5.2.8 and VICH GL23.

Current EFSA risk assessments classify porcine gelatin from Category 3 raw materials as negligible BSE risk — a significant regulatory advantage over bovine-sourced material, which requires more extensive TSE documentation in most dossier submissions.

Hard Gelatin Capsules — Structure, Manufacturing, and Specifications

Hard gelatin capsules are two-piece cylindrical shell systems: a body and a cap that engage by telescopic press-fit. The shell is produced in a standardised dipping process — precision steel pins are dipped in a hot gelatin solution, dried, stripped, cut to length, and joined. The manufacturing process demands tight gelatin specification control; batch-to-batch variability in Bloom or viscosity directly translates to shell weight variation and mechanical failure rates on high-speed filling lines.

Shell Composition and Moisture Control

HGC shells consist primarily of gelatin and water. Pigments, opacifiers (titanium dioxide), and colourants may be added. The gelatin used for HGC production typically runs 200–280 g Bloom — high enough to produce a rigid, self-supporting shell that survives mechanical filling and handling. Lower-Bloom material produces shells that dent and buckle on automated filling equipment.

Moisture content is the critical process variable in HGC manufacturing. Freshly formed shells contain 14–16% moisture; finished capsules at release must meet 13–16% MC per USP <661>. Below 13%, shells become brittle and crack during filling; above 16%, they soften and deform, causing cap-body separation and seal failures. Conditioning chambers between shell manufacture and filling maintain shells at controlled temperature and humidity to stabilise MC within specification.

Fill Material Compatibility

Hard gelatin capsules are designed for dry fill: powders, granulates, pellets, mini-tablets, and encapsulated beads. The API must flow freely enough to pass through dosing mechanisms — typically characterised by angle of repose and bulk density. APIs with poor flowability require granulation or formulation with glidants (colloidal silicon dioxide, magnesium stearate) before HGC filling.

Liquid fills in HGC are technically possible with thixotropic semi-solids (waxes, lipid bases), but require specialised banding or sealing to prevent leakage. True liquid fills are the domain of softgels.

Capsule Dimensions and Fill Volumes

Dissolution Profile

HGC shells dissolve in simulated gastric fluid at 37°C in 5–15 minutes under Ph. Eur. 2.9.3 apparatus 2 (paddle) conditions — one of the fastest-releasing solid oral dosage forms available. This makes HGC appropriate where rapid API release is the objective. Where delayed or enteric release is required, additional coating steps or modified gelatin formulations are applied.

Soft Gelatin Capsules — Structure, Manufacturing, and Specifications

Soft gelatin capsules are one-piece, hermetically sealed units produced by the rotary die encapsulation process (Scherer process, 1933 and its industrialised descendants). Two continuous gelatin ribbons are fed from temperature-controlled spreader boxes onto counter-rotating dies. The die pockets simultaneously form, fill, and seal the capsules in a single continuous operation — the fill material is injected into the forming capsule at precisely the moment the two ribbons are pressed together.

This process demands tighter gelatin rheology control than HGC shell dipping, because the ribbons must exhibit consistent thickness, elasticity, and thermal behaviour across a multi-hour production run.

Shell Composition and Plasticiser Ratio

SGC shells contain gelatin, plasticiser, and water in ratios determined by the target mechanical properties of the finished capsule. Glycerol and sorbitol are the primary plasticisers (both listed in FDA Inactive Ingredient Database for oral capsule use). The gelatin:plasticiser:water ratio in the wet gel mass typically runs in the approximate range of 1.0 : 0.4–0.6 : 1.0 by weight, though exact ratios are producer-specific and vary with the target shell hardness and fill material.

The gelatin grade used for SGC is 125–175 g Bloom — significantly lower than HGC requirements. This is deliberate: lower Bloom produces a more flexible, extensible gel ribbon that can be stretched over die cavities and sealed without cracking. Using HGC-grade gelatin (200–280 Bloom) in SGC production yields a ribbon that tears at the die interface, producing unacceptably high reject rates.

After the rotary die process, freshly formed SGC contain 30–40% moisture. They pass through a controlled drying tunnel where moisture is reduced to 6–10% MC — the specification for finished softgels. This drying step is critical to shell stability: over-dried capsules crack; under-dried capsules deform and soften under storage conditions.

Fill Material Compatibility

SGC fills are liquids or semi-solids: oils, lipid solutions, PEG-based vehicles, surfactant systems, and emulsions. The defining advantage is the ability to encapsulate APIs in a lipophilic matrix, which dramatically enhances bioavailability for poorly water-soluble compounds (BCS Class II and IV) through solubilisation and self-emulsifying drug delivery system (SEDDS) approaches.

However, fill-shell compatibility is a critical formulation constraint:

• Aldehydes generated by lipid peroxidation in unsaturated fatty acid fills (omega-3 oils, polyunsaturated seed oils) react with gelatin amino groups, inducing crosslinking. This is the primary stability failure mode for fish oil softgels.
• High-water-activity fills migrate into the shell, plasticising and deforming it.
• Low-molecular-weight alcohols and surfactants at high concentrations attack the shell, causing leakage.

Fill-shell compatibility studies conducted under ICH Q1A(R2) accelerated stability conditions (40°C/75%RH for 6 months) are mandatory before finalising the softgel formulation.

HGC vs. SGC — Head-to-Head Technical Comparison

Crosslinking: The Most Common Stability Failure in Gelatin Capsules

Crosslinking deserves its own section because it is the primary mechanism behind dissolution failures in gelatin capsule shelf-life studies — and because it is preventable with correct formulation and sourcing decisions.

When aldehydes present in the fill material, excipients, or packaging contact the gelatin shell, they react with free amino groups (primarily lysine side chains) in the gelatin protein, forming covalent crosslinks. The result is a shell that resists enzymatic digestion in gastric conditions, producing the characteristic insoluble pellicle during dissolution testing. A capsule that passes dissolution at release may fail at the 6- or 12-month time point as crosslinking progresses during storage.

Sources of aldehyde contamination include:

• Lipid peroxidation products in unsaturated oil fills (malondialdehyde, hexanal)
• Formaldehyde off-gassing from certain excipients (povidone, PVP, hydroxypropyl cellulose)
• Residual aldehydes in packaging materials
• Reducing sugars that generate aldehydes under Maillard conditions

Mitigation strategies include antioxidant addition to the fill (tocopherol, BHA, rosemary extract), nitrogen blanketing during encapsulation, selection of low-aldehyde excipients, modified gelatin formulations, or switching to HPMC where aldehyde exposure is uncontrollable.

Gelatin Grade Requirements — What Buyers Should Specify

A well-written pharmaceutical gelatin specification is the first line of defence against both performance failure and audit non-compliance. Based on Ph. Eur. 0330 requirements and the technical data published by Brodnica Gelatin's pharmaceutical gelatin team, a complete specification for pharmaceutical gelatin should include the following parameters with declared limits, not ranges:

Mandatory analytical parameters per batch CoA:

• Bloom strength (g) — declared grade ± tolerance
• Viscosity (mPa·s) — at 6.67% w/w, 60°C
• Loss on drying (%)
• Sulphated ash content (%)
• pH of 1% solution
• Sulphur dioxide (ppm, ≤50 per Ph. Eur. 0330)
• Heavy metals (Pb, As, Cd, Hg — per Annex III of Reg. EC 853/2004)
• Total aerobic microbial count
• Absence of Salmonella in 25 g
• Absence of E. coli

Mandatory compliance documentation:

• TSE/BSE declaration — species (Sus scrofa domesticus for porcine), tissue origin, country of origin, compliance with Ph. Eur. 5.2.8 and VICH GL23
• Category 3 raw material documentation per Regulation (EC) No 1069/2009
• GMP certificate — relevant framework: EudraLex Volume 4 (for EU pharmaceutical supply), EXCiPACT (dedicated excipient GMP scheme), or BRCGS Grade AA as a baseline food safety standard
• EU establishment approval number per Regulation (EC) No 853/2004, cross-referenceable against national competent authority registers

For pharmaceutical supply into EMA-regulated markets, a Certificate of Suitability (CEP) issued by EDQM significantly simplifies the CMC section of the dossier by providing EDQM's independent assessment that the gelatin complies with Ph. Eur. 0330. Not all suppliers hold a current CEP — verify scope and validity before referencing it in regulatory submissions.

Alternatives — When to Look Beyond Gelatin Capsules

A technically objective analysis must address alternatives. Two are commercially significant:

HPMC (hypromellose) capsules are indicated when the API generates aldehydes that drive gelatin crosslinking, when the product requires a vegan or BSE-free label claim, or when fill water activity is incompatible with gelatin stability. HPMC capsules typically cost substantially more per unit than gelatin equivalents — industry estimates generally range from 30–50% higher, though the actual differential varies by supplier, grade, and order volume, dissolve more slowly in acidic gastric conditions (which can affect dissolution specification compliance), and require validation on manufacturing lines originally designed for gelatin.

Pullulan capsules offer very low oxygen transmission rates (OTR) — relevant for oxygen-sensitive APIs — with full plant-based and vegan positioning. Unit cost is substantially higher than both gelatin and HPMC; the format is used in premium nutraceutical and biotech applications where OTR is a critical specification.

For most pharmaceutical applications — including the vast majority of generic and branded oral solid dose products — pharmaceutical gelatin remains the technically validated, regulatory-precedented, and cost-effective shell material. Where crosslinking is a formulation risk, it is often more efficient to address the root cause (antioxidant strategy, excipient selection) than to switch shell material.

The broader application potential of gelatin in pharmaceutical science — including its role in drug delivery matrices, haemostatic agents, and tissue-engineered constructs — is covered in the EGA's comprehensive review of gelatin in regenerative medicine, which demonstrates why gelatin's biocompatibility profile makes it a platform molecule well beyond the capsule shell.

Conclusion — Matching Capsule Type to Your Product Requirements

The decision between hard and soft gelatin capsules is a function of API physical form, bioavailability requirements, stability risk profile, and manufacturing infrastructure — not habit.

For solid APIs where rapid dissolution is the target, hard gelatin capsules remain the default choice: lower CAPEX, faster dissolution, simpler fill line qualification, and a regulatory track record that spans decades. For poorly water-soluble lipophilic APIs where bioavailability enhancement drives formulation strategy, softgels offer capabilities that no other oral solid dosage form matches.

In both cases, the gelatin specification is not a procurement afterthought — it is a formulation-critical variable that directly determines shell performance, dissolution behaviour, and stability outcomes. Buyers who specify gelatin grade, Bloom strength, viscosity, and compliance documentation as precisely as they specify any other critical excipient will experience fewer surprises at stability checkpoints and fewer delays in regulatory submissions.

For organisations evaluating pharmaceutical gelatin suppliers, Brodnica Gelatin's pharmaceutical gelatin production — a GMP-compliant, BRCGS Grade AA certified European producer of porcine Type A gelatin — provides the technical documentation, TSE/BSE compliance statements, and lot-specific CoA data that modern pharmaceutical qualification processes require. Their GMP standards article provides detailed context on the certification hierarchy and what each standard actually audits.

FAQ

Q1: What is the key difference between hard and soft gelatin capsules from a formulation perspective?

Hard gelatin capsules (HGC) are two-piece structures filled with dry API — powders, granulates, or pellets — that dissolve rapidly in gastric fluid (5–15 minutes at 37°C per Ph. Eur. 2.9.3). Soft gelatin capsules (SGC) are one-piece hermetically sealed units for liquid or semi-solid lipophilic fills, produced by the rotary die process. The gelatin grades required differ substantially: HGC uses 200–280 g Bloom for structural rigidity; SGC uses 125–175 g Bloom to produce the flexible, plasticised ribbon that the rotary die process demands.

Q2: Can the same pharmaceutical gelatin grade be used for both HGC and SGC manufacture?

No — not optimally. Although both formats require gelatin meeting Ph. Eur. 0330 or USP specifications, the required Bloom strength differs by approximately 100 g Bloom between the two applications. HGC-grade gelatin (200–280 g Bloom) in an SGC line produces ribbon that tears at the die; SGC-grade material (125–175 g Bloom) on an HGC dipping line yields shells with insufficient wall rigidity for automated filling. Suppliers should be asked to specify which grades are validated for each application.

Q3: What causes crosslinking in gelatin capsule shells and how does it affect dissolution testing?

Crosslinking occurs when aldehydes — from lipid peroxidation in unsaturated oil fills, from reducing sugars under Maillard conditions, or from certain excipients such as povidone — react with lysine amino groups in the gelatin shell, forming covalent intermolecular bonds that resist enzymatic digestion. The clinical consequence is a capsule that passes dissolution at release but develops an insoluble pellicle at later ICH stability time points (typically 6 or 12 months at accelerated or intermediate conditions). Detection requires a two-stage dissolution test with enzyme (simulated intestinal fluid with pepsin).

Q4: What regulatory documentation must a pharmaceutical gelatin supplier provide?

At minimum: a lot-specific Certificate of Analysis covering all Ph. Eur. 0330 parameters; a TSE/BSE compliance declaration identifying species, tissue origin, and country of origin; Category 3 raw material documentation per Regulation (EC) No 1069/2009; a current GMP certificate (EudraLex Volume 4 applicable scope, EXCiPACT, or BRCGS Grade AA); and EU establishment approval under Regulation (EC) No 853/2004. For EMA regulatory submissions, a Certificate of Suitability (CEP) from EDQM simplifies the CMC dossier by providing independent pharmacopoeial conformity assessment.

Q5: When should formulators choose HPMC capsules over pharmaceutical gelatin?

HPMC is indicated when the API generates aldehydes that drive gelatin crosslinking and cannot be adequately controlled through antioxidant strategy or excipient selection; when the product must carry a vegan or BSE-free label claim for target market requirements; or when fill water activity is incompatible with gelatin shell stability. The trade-offs are real: HPMC capsules cost approximately 30–50% more per unit, dissolve more slowly in low-pH gastric conditions (which may require dissolution specification adjustment), and require line qualification on equipment originally designed for gelatin. These considerations, not a preference for one shell material over another, should drive the decision.

Sources: Ph. Eur. Monograph 0330 (Gelatina); USP Gelatin General Notices; Ph. Eur. 5.2.8 (TSE/BSE); VICH GL23; ICH Q1A(R2) Stability Testing; EU GMP Commission Guidelines on formalised risk assessment for excipients (2015/C 95/02); Regulation (EC) No 853/2004, Annex III, Section XIV; Regulation (EC) No 1069/2009 (Animal By-Products); Regulation (EU) No 2073/2005 (Microbiological Criteria); EMA Guideline on minimising TSE risk (EMEA/410/01 Rev. 3); Capsugel/Lonza HGC/SGC technical data; EFSA Journal (2024): BSE risk from porcine collagen and gelatin; GMIA Standard Methods for Testing Edible Gelatin; BRCGS Food Safety Standard Issue 9; EXCiPACT GMP/GDP Certification Standards for Pharmaceutical Excipient Suppliers.